31-Dec-23 | 31-Dec-22 | 31-Dec-21 | 31-Dec-20 | 31-Dec-19 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Asia, Africa & Australasia | n/a | n/a | n/a | n/a | 12,323.00 | 33% | 9,728.00 | 37% | 9,073.00 | 37% |
Continental Europe | n/a | n/a | n/a | n/a | 7,827.00 | 21% | 4,836.00 | 18% | 4,162.00 | 17% |
Rest of Europe | 9,725.00 | 21% | 8,909.00 | 20% | n/a | n/a | n/a | n/a | n/a | n/a |
The Americas | n/a | n/a | 19,619.00 | 44% | 14,022.00 | 37% | 10,312.00 | 39% | 9,327.00 | 38% |
UK | 3,368.00 | 7% | 3,117.00 | 7% | 3,245.00 | 9% | 1,741.00 | 7% | 1,822.00 | 7% |
Unanalysed | 32,718.00 | 71% | 12,706.00 | 29% | n/a | n/a | n/a | n/a | n/a | n/a |
Total | 45,811.00 | 100% | 44,351.00 | 100% | 37,417.00 | 100% | 26,617.00 | 100% | 24,384.00 | 100% |
Profit Before Tax | ||||||||||
Asia, Africa & Australasia | n/a | n/a | n/a | n/a | 931.00 | n/a | 745.00 | 19% | n/a | n/a |
Continental Europe | n/a | n/a | n/a | n/a | 2,682.00 | n/a | 2,356.00 | 60% | n/a | n/a |
Rest of Europe | 4,999.00 | n/a | 2,709.00 | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
The Americas | n/a | n/a | (1,140.00) | n/a | (2,401.00) | n/a | 297.00 | 8% | n/a | n/a |
UK | (577.00) | n/a | 272.00 | n/a | (1,477.00) | n/a | 518.00 | 13% | n/a | n/a |
Unanalysed | 2,477.00 | n/a | 660.00 | n/a | n/a | n/a | n/a | n/a | 1,548.00 | 100% |
Total | 6,899.00 | n/a | 2,501.00 | n/a | (265.00) | n/a | 3,916.00 | 100% | 1,548.00 | 100% |
31-Dec-23 | 31-Dec-22 | 31-Dec-21 | 31-Dec-20 | 31-Dec-19 | ||||||
---|---|---|---|---|---|---|---|---|---|---|
Revenue | ||||||||||
Cardiovascular, Renal & Metabolism | 10,585.00 | 23% | 9,188.00 | 18% | n/a | n/a | n/a | n/a | n/a | n/a |
Cardiovascular, Renal and Metabolism | n/a | n/a | 9,188.00 | 18% | 8,088.00 | 22% | 7,096.00 | 27% | n/a | n/a |
Covid-19 | n/a | n/a | n/a | n/a | n/a | n/a | 2.00 | n/a | n/a | n/a |
Oncology | 17,145.00 | 39% | 14,631.00 | 28% | 12,940.00 | 37% | 10,850.00 | 47% | n/a | n/a |
Other | 1,176.00 | 3% | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Others | n/a | n/a | 1,625.00 | 3% | n/a | n/a | n/a | n/a | n/a | n/a |
Rare Disease | 7,764.00 | 18% | 7,053.00 | 14% | 3,110.00 | 9% | n/a | n/a | n/a | n/a |
Respiratory & Immunology | 6,107.00 | 14% | 5,765.00 | 11% | 6,034.00 | 17% | 5,357.00 | 23% | n/a | n/a |
Unanalysed | 2,022.00 | n/a | (7,835.00) | n/a | 2,580.00 | n/a | 3,312.00 | n/a | n/a | n/a |
Vaccines & Immune Therapies | 1,012.00 | 2% | 4,736.00 | 9% | 4,665.00 | 13% | n/a | n/a | n/a | n/a |
Total | 45,811.00 | 100% | 44,351.00 | 100% | 37,417.00 | 100% | 26,617.00 | 100% | 24,384.00 | n/a |
Profit Before Tax | ||||||||||
Unanalysed | 6,899.00 | n/a | 2,501.00 | n/a | (265.00) | n/a | 3,916.00 | n/a | n/a | n/a |
Total | 6,899.00 | n/a | 2,501.00 | n/a | (265.00) | n/a | 3,916.00 | n/a | 1,548.00 | n/a |
You are here: research